We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bioneer Named Exclusive Distributor of Sequenom's Genetic Analysis Products in South Korea

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bioneer Named Exclusive Distributor of Sequenom's Genetic Analysis Products in South Korea"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Sequenom, Inc. and Bioneer Corporation have announced that Bioneer has been selected to exclusively distribute and promote Sequenom's genetic analysis products in South Korea.

Under a separate agreement, Bioneer will also operate a core facility that will provide contract services for human, livestock, and agricultural applications throughout South Korea, with potential for expansion into additional territories and markets, using Sequenom's MassARRAY® system and consumable products.

"We are very pleased to partner with Sequenom. Sequenom's products and our service offerings using Sequenom's technology should enable Bioneer to provide life scientists and clinicians in Korea with the high performance tools and data they need to unlock the genetic basis of human disease," said Dr. Han-Oh Park, President and Chief Executive Officer of Bioneer.

"With the addition of these products and services, Bioneer now offers a comprehensive life sciences portfolio of technology solutions that also includes tools for drug development and screening, and diagnostics."

Under the agreements, Bioneer will offer MassARRAY-based product and service solutions for fine mapping genotyping, gene and biomarker discovery, validation, and screening, DNA methylation marker pattern analysis (epigenetic studies), and quantitative gene expression analysis.

"We are seeing increased demand for genetic analysis solutions in the Asia-Pacific region and our partnership with Bioneer should help us maximize our market penetration in South Korea," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom.

"We are excited to be partnering with such a highly regarded life sciences provider and we look forward to making the most of our market opportunities in South Korea."